Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

Statistical Methods for Rates and Proportions

Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646

Neuropathological stageing of Alzheimer-related changes.

Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 4×

Statistical Methods for Rates and Proportions.

Everitt, B. S., & Fleiss, J. L. (1981) · Biometrics · doi:10.2307/2530193 · Cited by 9,034

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease

Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321

National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092

Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

Fillenbaum, G., & Heyman, A. (2002) · doi:10.1002/0470846410.ch42(iii · Cited by 2,859

Revising the definition of Alzheimer's disease: a new lexicon

Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869

Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.

Scheltens, P., Leys, D., Barkhof, F., Huglo, D. G., Weinstein, H. C., Vermersch, P., Kuiper, M. A., Steinling, M., Wolters, E. C., & Valk, J. (1992) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.10.967 · Cited by 1,811

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117

Correction to: Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia

Thal, D. R., Ronisz, A., Tousseyn, T., Upadhaya, A. R., Balakrishnan, K., Vandenberghe, R. R., Vandenbulcke, M., Arnim, C. A. F. V., Otto, M., Beach, T. G., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01005-5 · Cited by 25

Innovative Molecular Imaging for Clinical Research, Therapeutic Stratification, and Nosography in Neuroscience

Beaurain, M., Salabert, A., Ribeiro, M. J., Arlicot, N., Damier, P., Jeune, F. L., Démonet, J., & Payoux, P. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00268 · Cited by 26

Neuronal PET tracers for Alzheimer's disease.

Kumar, A. P., Singh, N., Nair, D. R., & Justin, A. (2021) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2021.11.093 · Cited by 15

Standardized Uptake Value Ratio-Independent Evaluation of Brain Amyloidosis

Chincarini, A., Sensi, F., Rei, L., Bossert, I., Morbelli, S. D., Guerra, U. P., Frisoni, G. B., Padovani, A., Nobili, F. M., & Initiative, A. D. N. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160232 · Cited by 27

A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies

Perani, D., Iaccarino, L., Lammertsma, A. A., Windhorst, A. D., Edison, P., Boellaard, R., Hansson, O., Nordberg, A. K., Jacobs, A. H., & IMBI Project (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.02.004 · Cited by 25

Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression

Kotari, V., Southekal, S. S., Navitsky, M. A., Kennedy, I. A., Lu, M., Morris, A., Zimmer, J. A., Fleisher, A., Mintun, M. A., Devous, M. D., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01160-6 · Cited by 25

A new integrated dual time-point amyloid PET/MRI data analysis method

Cecchin, D., Barthel, H., Poggiali, D., Cagnin, A., Tiepolt, S., Zucchetta, P., Turco, P., Gallo, P., Frigo, A. C., Sabri, O., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3750-0 · Cited by 23

Tau PET positivity predicts clinically relevant cognitive decline driven by Alzheimer’s disease compared to comorbid cases; proof of concept in the ADNI study

Ioannou, K., Bucci, M., Tzortzakakis, A., Savitcheva, I., Nordberg, A. K., Chiotis, K., & Initiative, A. D. N. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02672-9 · Cited by 35

Outcome Measures for Disease-Modifying Trials in Parkinson’s Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative

Gonzalez‐Robles, C., Weil, R. S., van Wamelen, D. J., Bartlett, M., Burnell, M., Clarke, C. S., Hu, M. T., Huxford, B., Jha, A., Lambert, C., et al. (2023) · Journal of Parkinson s Disease · doi:10.3233/jpd-230051 · Cited by 25

Combination Therapy in Alzheimer’s Disease: Is It Time?

Salehipour, A., Bagheri, M., Sabahi, M., Dolatshahi, M., & Boche, D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215680 · Cited by 22

Reproducibility of Alzheimer’s Disease Cerebrospinal Fluid-Biomarker Measurements under Clinical Routine Conditions

Vogelgsang, J. S., Wedekind, D., Bouter, C., Klafki, H.-W., & Wiltfang, J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170793 · Cited by 22

Glitter in the Darkness? Nonfibrillar β-Amyloid Plaque Components Significantly Impact the β-Amyloid PET Signal in Mouse Models of Alzheimer Disease

Biechele, G., Monasor, L. S., Wind-Mark, K., Blume, T., Parhizkar, S., Arzberger, T., Sacher, C., Beyer, L., Eckenweber, F., Gildehaus, F., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.261858 · Cited by 20

Future Directions in Imaging Neurodegeneration

Masdeu, J. C. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0718-1 · Cited by 22

Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice

Shaw, L. M. J., Korecka, M., Figurski, M., Toledo, J. B., Irwin, D. J., Kang, J., & Trojanowski, J. Q. (2019) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2019.029587 · Cited by 21

Toward a Universal Readout for18F-Labeled Amyloid Tracers: The CAPTAINs Study

Bischof, G. N., Bartenstein, P., Barthel, H., van Berckel, B. N. M., Doré, V., van Eimeren, T., Foster, N. L., Hammes, J., Lammertsma, A. A., Minoshima, S., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.250290 · Cited by 21

Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease

Aichholzer, F., Klafki, H., Ogorek, I., Vogelgsang, J. S., Wiltfang, J., Scherbaum, N., Weggen, S., & Wirths, O. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00828-1 · Cited by 23

Active Gains in brain Using Exercise During Aging (AGUEDA): protocol for a randomized controlled trial

Solis‐Urra, P., Molina‐Hidalgo, C., García‐Rivero, Y., Costa-Rodríguez, C., Mora-González, J., Fernandez‐Gamez, B., Olvera‐Rojas, M., Coca‐Pulido, A., Toval, Á., Bellón, D., et al. (2023) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2023.1168549 · Cited by 21

Blood-based CNS regionally and neuronally enriched extracellular vesicles carrying pTau217 for Alzheimer’s disease diagnosis and differential diagnosis

Guo, Z., Tian, C., Shi, Y., Song, X., Yin, W., Tao, Q., Liu, J., Peng, G.-P., Wu, Z., Wang, Y., et al. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01727-w · Cited by 23

Association between white matter lesions and cerebral Aβ burden

Yi, H., Won, K. S., Chang, H. W., & Kim, H. W. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204313 · Cited by 21

Reductions in the white–gray functional connectome in preclinical Alzheimer's disease and their associations with amyloid and cognition

Xu, L., Zhao, Y., Choi, S., Li, M., Schilling, K. G., Zu, Z., Rogers, B. P., Ding, Z., Anderson, A. W., Landman, B. A., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14334 · Cited by 20

PET Neuroimaging in Dementia Conditions

Perani, D., Caminiti, S. P., Carli, G., & Tondo, G. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_9 · Cited by 20

Targeting amyloid proteins for clinical diagnosis of neurodegenerative diseases

Zhang, S., Dong, H., Bian, J., Li, D., & Liu, C. (2022) · Fundamental Research · doi:10.1016/j.fmre.2022.10.009 · Cited by 23

Amyloid Positron Emission Tomography and Subsequent Health Care Use Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia

Rabinovici, G. D., Carrillo, M. C., Apgar, C., Gareen, I. F., Gutman, R., Hanna, L., Hillner, B. E., March, A., Romanoff, J., Siegel, B. A., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.3490 · Cited by 20

Differences in baseline cognitive performance between participants with early‐onset and late‐onset Alzheimer's disease: Comparison of LEADS and ADNI

Hammers, D. B., Eloyan, A., Thangarajah, M., Taurone, A., Beckett, L. A., Gao, S., Polsinelli, A. J., Kirby, K., Dage, J. L., Nudelman, K. N. H., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14218 · Cited by 22

Quantitative susceptibility mapping in β-Amyloid PET-stratified patients with dementia and healthy controls – A hybrid PET/MRI study

Tiepolt, S., Rullmann, M., Jochimsen, T. H., Gertz, H., Schroeter, M. L., Patt, M., Sabri, O., & Barthel, H. (2020) · European Journal of Radiology · doi:10.1016/j.ejrad.2020.109243 · Cited by 20

Circular Inference in Dementia Diagnostics

Høilund‐Carlsen, P. F., Barrio, J. R., GJEDDE, A. H., Werner, T. J., & Alavi, A. A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180050 · Cited by 20

The 2024 NIA-AA biological definition of Alzheimer’s disease: linking biomarkers to clinical practice

Kobayashi, G., Hirata, K., Ono, M., Kasuga, K., & Takado, Y. (2026) · Frontiers in Dementia · doi:10.3389/frdem.2026.1736297 · Cited by 22

New protein deposition tracers in the pipeline

Jovalekic, A., Koglin, N., Mueller, A., & Stephens, A. W. (2016) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-016-0015-3 · Cited by 19

Dielectric Measurements of Brain Tissues with Alzheimer’s Disease Pathology in the Microwave Region

Saied, I., Bashri, M. S. R., Arslan, T., Smith, C., & Chandran, S. (2019) · IEEE International Symposium on Medical Measurements and Applications (MeMeA) · doi:10.1109/memea.2019.8802179 · Cited by 19

(+)-[18F]Flubatine as a novel α4β2 nicotinic acetylcholine receptor PET ligand—results of the first-in-human brain imaging application in patients with β-amyloid PET-confirmed Alzheimer’s disease and healthy controls

Tiepolt, S., Becker, G., Wilke, S., Cecchin, D., Rullmann, M., Meyer, P., Barthel, H., Hesse, S., Patt, M., Luthardt, J., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05029-w · Cited by 13

Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration

Blazhenets, G., Frings, L., Ma, Y., Sörensen, A., Eidelberg, D., Wiltfang, J., Meyer, P. T., & Initiative, A. D. N. (2021) · Neurology · doi:10.1212/wnl.0000000000011521 · Cited by 21

Study Design and Baseline Results in a Cohort Study to Identify Predictors for the Clinical Progression to Mild Cognitive Impairment or Dementia From Subjective Cognitive Decline (CoSCo) Study

Ho, S. H., Hong, Y. J., Jeong, J. H., Park, K. H., Kim, S., Wang, M. J., Choi, S. H., Han, S., & Yang, D. W. (2022) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2022.21.4.147 · Cited by 19

Differences between ante mortem Alzheimer's disease biomarkers in predicting neuropathology at autopsy

Wang, Z., Tan, L., Wang, H.-F., Chen, S., Fu, Y., Gao, P., Ma, Y., Guo, Y., Hou, J., Zhang, D., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12997 · Cited by 20

Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes

Weston, P. S. J., Paterson, R. W., Marc Modat, A., Burgos, N., Cardoso, M. J., Magdalinou, N. K., Lehmann, M., Dickson, J. C., Barnes, A., Bomanji, J. B., et al. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.10.001 · Cited by 19

Feasibility of in vivo 18F-florbetaben PET/MR imaging of human carotid amyloid-β

Bucerius, J. A., Barthel, H., Tiepolt, S., Werner, P., Sluimer, J. C., Wildberger, J. E., Patt, M., Hesse, S., Gertz, H., Biessen, E. A. L., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3651-2 · Cited by 18

Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET

Brendel, M., Schnabel, J., Schönecker, S., Wagner, L., Brendel, E., Meyer-Wilmes, J., Unterrainer, M., Schildan, A., Patt, M., Prix, C., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3832-z · Cited by 19

Association of β-Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra

Yoo, H. S., Jeon, S., Cavedo, E., Ko, M., Yun, M., Lee, P. H., Sohn, Y. H., Grothe, M. J., Teipel, S., Hampel, H. J., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000013277 · Cited by 21

Status and trends in the development of clinical diagnostic agents

Opacic, T., Paefgen, V., Lammers, T., & Kiessling, F. M. (2016) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1441 · Cited by 20

Imaging and Fluid Biomarkers of Alzheimer Disease: Complementation Rather Than Competition

Drzezga, A. E., & Barthel, H. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270152 · Cited by 18

Advances in PET imaging of protein aggregates associated with neurodegenerative disease

Higuchi, M., Tagai, K., Takahata, K., & Endo, H. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01126-2 · Cited by 21

Novel Tracers and Radionuclides in PET Imaging

Mason, C. A., Gimblet, G. R., Lapi, S. E., & Lewis, J. S. (2021) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2021.05.012 · Cited by 19

Dynamic network model reveals distinct tau spreading patterns in early- and late-onset Alzheimer disease

Lee, W. J., Cho, H., Baek, M. S., Kim, H., Lee, J., Ryu, Y. H., Lyoo, C. H., & Seong, J. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01061-0 · Cited by 20

Review of triazole scaffolds for treatment and diagnosis of Alzheimer's disease

Li, Q., Qi, S., Liang, J., Tian, Y., He, S., Liao, Q., Xing, S., Han, L., & Chen, X. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110623 · Cited by 19

PRedicting the EVolution of SubjectIvE Cognitive Decline to Alzheimer’s Disease With machine learning: the PREVIEW study protocol

Mazzeo, S., Lassi, M., Padiglioni, S., Vergani, A. A., Moschini, V., Scarpino, M., Giacomucci, G., Burali, R., Morinelli, C., Fabbiani, C., et al. (2023) · BMC Neurology · doi:10.1186/s12883-023-03347-8 · Cited by 19

Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap

Frisoni, G. B., Perani, D., Bastianello, S., Bernardi, G., Porteri, C., Boccardi, M., Cappa, S. F., Trabucchi, M., & Padovani, A. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.033 · Cited by 18

Antemortem-Postmortem Correlation of Florbetapir ( 18 F) PET Amyloid Imaging with Quantitative Biochemical Measures of Aβ 42 but not Aβ 40

Beach, T. G., Maarouf, C. L., Intorcia, A. J., Sue, L. I., Serrano, G. E., Lu, M., Joshi, A. D., Pontecorvo, M. J., & Roher, A. E. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170762 · Cited by 18

The Association of β-Amyloid with Cognition and Striatal Dopamine in Early, Non-Demented Parkinson’s Disease

Oh, Y.-S., Yoo, S.-W., Lyoo, C. H., Yoo, J.-Y., Yoon, H., Ha, S., Lee, K.-S., & Kim, J.-S. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202496 · Cited by 19

Identifying novel genetic variants for brain amyloid deposition: a genome-wide association study in the Korean population

Kim, H.-R., Jung, S.-H., Kim, J., Kang, S. H., Kang, S. H., Hwangbo, S., Kim, J. P., Kim, B., Kim, S., Kim, S., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00854-z · Cited by 18

Cerebrospinal Fluid, MRI, and Florbetaben-PET in Cerebral Amyloid Angiopathy-Related Inflammation

Renard, D., Collombier, L., Dematteï, C., Wacongne, A., Charif, M., Ayrignac, X., Azakri, S., Gaillard, N., Boudousq, V., Lehmann, S., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170843 · Cited by 19

Potential utility of plasma pTau217 for assessing amyloid and tau biomarker profiles

Shin, D., Jang, H., Yoo, H., Kim, K., Zetterberg, H., Blennow, K., González‐Ortiz, F., Ashton, N. J., Lee, E. H., Yun, J., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07457-y · Cited by 18

The Role of Amyloid- and Tau PET in the New Era of Alzheimer Disease Therapies

Chiotis, K., Wang, Y., Joie, R. L., & Rabinovici, G. D. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268339 · Cited by 18

Association of PET‐based stages of amyloid deposition with neuropathological markers of Aβ pathology

Teipel, S. J., Temp, A. G. M., Levin, F., Dyrba, M., Grothe, M. J., & Initiative, A. D. N. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51238 · Cited by 17

Implication of metabolic and dopamine transporter PET in dementia with Lewy bodies

Kang, S. W., Jeon, S., Lee, Y., Park, M.-C., Baik, K., Jung, J. H., Chung, S. J., Yoo, H. S., Jeong, S. H., Yun, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93442-y · Cited by 17

Structural biomarker‐based Alzheimer's disease detection via ensemble learning techniques

Shukla, A., Tiwari, R., & Tiwari, S. (2023) · International Journal of Imaging Systems and Technology · doi:10.1002/ima.22967 · Cited by 17

[18F]-D3FSP β-amyloid PET imaging in older adults and alzheimer’s disease

Li, A., Zhao, R., Zhang, M., Sun, P., Cai, Y. Q., Zhu, L., Kung, H. F., Han, Y., Wang, X., & Guo, T. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06835-2 · Cited by 17

The role of neuroimaging in Alzheimer’s disease: implications for the diagnosis, monitoring disease progression, and treatment

Mulumba, J., Duan, R., Luo, B., Wu, J., Sulaiman, M., Wang, F., & Yang, Y. (2025) · Exploration of neuroscience · doi:10.37349/en.2025.100675 · Cited by 23

AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention

Meyer, P., McSweeney, M., Gonneaud, J., & Villeneuve, S. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.05.001 · Cited by 20

Translating amyloid PET of different radiotracers by a deep generative model for interchangeability

Kang, S. K., Choi, H., & Lee, J. S. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.117890 · Cited by 17

Association of β-Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra.

Yoo, H. S., Jeon, S., Evans, A. C., Ye, B. S., Cavedo, E., Ko, M., Yun, M., Lee, P. H., Sohn, Y. H., Grothe, M. J., et al. (2022) · DZNE Pub · Cited by 17

Predominant subcortical accumulation of 18 F-flortaucipir binding in behavioral variant frontotemporal dementia

Cho, H., Seo, S. W., Choi, J. Y., Lee, H. S., Ryu, Y. H., Lee, M. S., Na, D. L., Kim, H. J., & Lyoo, C. H. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.02.015 · Cited by 19

Synergy between the alteration in the N-terminal region of butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer’s disease

Jasiecki, J., Limon-Sztencel, A., Żuk, M., Chmara, M., Cysewski, D., Limon, J., & Wasąg, B. (2019) · Scientific Reports · doi:10.1038/s41598-019-41578-3 · Cited by 17

Whole brain optoacoustic tomography reveals strain-specific regional beta-amyloid densities in Alzheimer’s disease amyloidosis modelsPreprint

Ni, R., Deán‐Ben, X. L., Kirschenbaum, D. S., Rudin, M., Chen, Z., Crimi, A., Voigt, F. F., Nilsson, K. P. R., Helmchen, F., Nitsch, R. M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.25.964064 · Cited by 17

Targeted examination of amyloid beta and tau protein accumulation via positron emission tomography for the differential diagnosis of Alzheimer’s disease based on the A/T(N) research framework

Wang, Y., Zhang, Y., & Yu, E. (2023) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2023.108071 · Cited by 16

Design, Synthesis, and Preliminary Evaluation of SPECT Probes for Imaging β-Amyloid in Alzheimer’s Disease Affected Brain

Okumura, Y., Maya, Y., Onishi, T., Shoyama, Y., Izawa, A., Nakamura, D., Tanifuji, S., Tanaka, A., Arano, Y., & Matsumoto, H. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00064 · Cited by 16

Proteomic profiles of prevalent mild cognitive impairment and Alzheimer's disease among adults with Down syndrome

Petersen, M. E., Zhang, F., Krinsky‐McHale, S. J., Silverman, W. P., Lee, J. H., Pang, D. I., Hall, J. R., Schupf, N., & O’Bryant, S. E. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12023 · Cited by 15

Apolipoprotein E4, amyloid, and cognition in Alzheimer's and Lewy body disease

Jung, J. H., Jeon, S., Baik, K., Lee, Y. H., Chung, S. J., Yoo, H. S., Jeong, S. H., Sohn, Y. H., Lee, P. H., & Ye, B. S. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.06.004 · Cited by 16

Matching Clinical Diagnosis and Amyloid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia

Giacomucci, G., Mazzeo, S., Bagnoli, S., Casini, M., Padiglioni, S., Polito, C., Berti, V., Balestrini, J., Ferrari, C., Lombardi, G., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11010047 · Cited by 16

Fluorine-18 Radiolabeling Strategies—Advantages and Disadvantages of Currently Applied Labeling Methods

Edem, P. E., Stéen, E. J. L., Kjær, A., & Herth, M. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812958-6.00002-1 · Cited by 16

Cerebrospinal fluid from Alzheimer’s disease patients as an optimal formulation for therapeutic application of mesenchymal stem cells in Alzheimer’s disease

Lee, J., Kwon, S. J., Kim, J. H., Jang, H., Lee, N. K., Hwang, J. W., Kim, J. H., Chang, J. W., & Na, D. L. (2019) · Scientific Reports · doi:10.1038/s41598-018-37252-9 · Cited by 18

High Correlation of Static First-Minute-Frame (FMF) PET Imaging after 18F-Labeled Amyloid Tracer Injection with [18F]FDG PET Imaging

Seiffert, A. P., Gómez‐Grande, A., Villarejo‐Galende, A., González‐Sánchez, M., Bueno, H., Aguilera, E. J. G., & González, P. S. (2021) · Sensors · doi:10.3390/s21155182 · Cited by 15

Altered metamemory precedes cognitive impairment in subjective cognitive decline with positive amyloid-beta

Li, Q., Pan, F., Huang, Q., Lo, C. Z., Xie, F., & Guo, Q. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1046445 · Cited by 16

Impacts of baseline biomarkers on cognitive trajectories in subjective cognitive decline: the CoSCo prospective cohort study

Hong, Y. J., Ho, S. H., Jeong, J. H., Park, K. H., Kim, S., Wang, M. J., Choi, S. H., Yang, D. W., & CoSCo study group (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01273-y · Cited by 15

Molecular imaging: What is right and what is an illusion?

Klunk, W. E. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.01.004 · Cited by 15

Neuroimaging of Diseases Causing Dementia

Masdeu, J. C. (2019) · Neurologic Clinics · doi:10.1016/j.ncl.2019.08.003 · Cited by 16

Effect of A/T/N imaging biomarkers on impaired odor identification in Alzheimer's disease

Baek, M. S., Cho, H., Lee, H. S., Lee, J., Ryu, Y. H., & Lyoo, C. H. (2020) · Scientific Reports · doi:10.1038/s41598-020-68504-2 · Cited by 15

Amyloid PET in Sporadic Early‐ Versus Late‐Onset Alzheimer's Disease: Comparison of the LEADS and ADNI Cohorts

Lagarde, J., Maiti, P., Schonhaut, D. R., Blazhenets, G., Zhang, J., Eloyan, A., Thangarajah, M., Taurone, A., Allen, I. E., Soleimani‐Meigooni, D. N., et al. (2025) · Annals of Neurology · doi:10.1002/ana.27233 · Cited by 14

The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment

Kim, H., Oh, J. S., Lim, J., Lee, S., Jo, S., Chung, E.-N., Shim, W. H., Oh, M., Kim, J. S., Roh, J. H., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01035-2 · Cited by 14

Quantitative comparative analysis of amyloid PET images using three radiopharmaceuticals

Jeong, Y. J., Yoon, H. J., Kang, D., & Park, K. W. (2023) · Annals of Nuclear Medicine · doi:10.1007/s12149-023-01824-1 · Cited by 14

The role of plasma neurofilament light chain and glial fibrillary acidic protein in subjective cognitive decline and mild cognitive impairment

Mazzeo, S., Ingannato, A., Giacomucci, G., Bagnoli, S., Cavaliere, A., Moschini, V., Balestrini, J., Morinelli, C., Galdo, G., Emiliani, F., et al. (2023) · Neurological Sciences · doi:10.1007/s10072-023-07065-4 · Cited by 14

Association of Hippocampal Subfield Volumes with Amyloid-Beta Deposition in Alzheimer’s Disease

Baek, M. S., Lee, N., Kim, J. W., & Hong, J. Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061526 · Cited by 14

The Impact of Amyloid-Beta Positivity with 18F-Florbetaben PET on Neuropsychological Aspects in Parkinson’s Disease Dementia

Na, S., Jeong, H. S., Park, J., Chung, Y., & Song, I. (2020) · Metabolites · doi:10.3390/metabo10100380 · Cited by 14

New Therapeutics in Alzheimer’s Disease Longitudinal Cohort study (NTAD): study protocol

Lanskey, J. H., Kocagoncu, E., Quinn, A. J., Cheng, Y.-J., Karadag, M., Pitt, J., Lowe, S., Perkinton, M., Raymont, V., Singh, K. D., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-055135 · Cited by 10

Comparison Between 18F-Florapronol and 18F-Florbetaben Imaging in Patients With Cognitive Impairment

Baik, K., Jeon, S., Park, M., Lee, Y., Lee, P. H., Sohn, Y. H., & Ye, B. S. (2023) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.0207 · Cited by 13

Software compatibility analysis for quantitative measures of [18F]flutemetamol amyloid PET burden in mild cognitive impairment

Pemberton, H., Buckley, C. J., Battle, M. R., Bollack, A., Patel, V., Tomova, P., Cooke, D., Balhorn, W., Hegedorn, K., Lilja, J., et al. (2023) · EJNMMI Research · doi:10.1186/s13550-023-00994-3 · Cited by 13

The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI)

Mormino, E. C., Biber, S., Rahman‐Filipiak, A., Arfanakis, K., Clark, L. R., Dage, J. L., Detre, J. A., Dickerson, B. C., Donohue, M., Kecskemeti, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14383 · Cited by 15

Monoamine oxidase binding not expected to significantly affect [18F]flortaucipir PET interpretation

Wright, J. P., Goodman, J. R., Lin, Y., Lieberman, B. P., Clemens, J., Gomez, L. F., Liang, Q., Hoye, A. T., Pontecorvo, M. J., & Conway, K. A. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05822-9 · Cited by 13

Effect of Amyloid on Cognitive Performance in Parkinson's Disease and Dementia with Lewy Bodies

Baik, K., Kim, H. R., Park, M.-C., Lee, Y., Na, H. K., Sohn, Y. H., Seong, J., & Lee, P. H. (2022) · Movement Disorders · doi:10.1002/mds.29295 · Cited by 13

Correlation of florbetaben PET imaging and the amyloid peptide Aß42 in cerebrospinal fluid

Schipke, C. G., Koglin, N., Bullich, S., Joachim, L. K., Haas, B., Seibyl, J. P., Barthel, H., Sabri, O., & Peters, O. (2016) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2016.10.011 · Cited by 13

18F-Florbetaben Amyloid PET Imaging: A Chinese Study in Cognitive Normal Controls, Mild Cognitive Impairment, and Alzheimer’s Disease Patients

Chang, Y. Z., Li, C., Yang, H., Wu, Y., Xu, B., Zhang, J., & Wang, R. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00745 · Cited by 14

Feasibility Study: Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases

Serrano, G. E., Intorcia, A. J., Carew, J., Chiarolanza, G., Hidalgo, J. A., Sue, L. I., Dugger, B. N., Saxon‐LaBelle, M., Filon, J. R., Scroggins, A., et al. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000235 · Cited by 13

Head‐to‐head comparison of cerebral blood flow single‐photon emission computed tomography and 18F‐fluoro‐2‐deoxyglucose positron emission tomography in the diagnosis of Alzheimer disease

Nadebaum, D. P., Krishnadas, N., Poon, A. M. T., Kalff, V., Lichtenstein, M., Villemagne, V. L., Jones, G. R., & Rowe, C. C. (2020) · Internal Medicine Journal · doi:10.1111/imj.14890 · Cited by 13

Update on the Cognitive Presentations of iNPH for Clinicians

Langheinrich, T., Chen, C., & Thomas, O. M. T. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.894617 · Cited by 11

Prediction of amyloid PET positivity via machine learning algorithms trained with EDTA-based blood amyloid-β oligomerization data

Youn, Y. C., Kim, H. R., Shin, H.-W., Jeong, H.-B., Han, S., Pyun, J., Ryoo, N., Park, Y. H., & Kim, S. (2022) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-022-02024-z · Cited by 12

An autonomic mode of brain activity

Kojori, E. S., Tomasi, D. G., Demiral, Ş. B., Wang, G., & Volkow, N. D. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102510 · Cited by 11

Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice

Jack, C. R., Graf, A., Burnham, S. C., Doty, E. G., Moebius, H. J., Montenigro, P. H., Siemers, E., Sink, K. M., Shaw, L. M. J., Hansen, C. T., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70013 · Cited by 15

Analytical and clinical validation of a high accuracy fully automated digital immunoassay for plasma phospho-Tau 217 for clinical use in detecting amyloid pathology

Wilson, D. H., Khare, M., Triana‐Baltzer, G., Wolfe, M., Sheehy, P., Copeland, K. A. F., Hesterberg, L. K., Vasko, A.-J., van der Flier, W. M., Verberk, I. M. W., et al. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1568971 · Cited by 12

Clinical Utility of 18F-Florbetaben PET for Detecting Amyloidosis Associated With Multiple Myeloma

Seo, M., Cha, H. J., Kim, M., Park, S. H., Lim, J. H., Choi, Y., Lee, Y. J., Park, S. H., & Jo, J. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002699 · Cited by 12

Principal components of tau positron emission tomography and longitudinal tau accumulation in Alzheimer’s disease

Cho, H., Baek, M. S., Lee, H. S., Lee, J., Ryu, Y. H., & Lyoo, C. H. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00685-4 · Cited by 13

Paradoxical Cerebral Perfusion in Parkinson’s Disease Patients with Orthostatic Hypotension: A Dual-Phase 18F-Florbetaben Positron Emission Tomography Study

Yoo, S., Ha, S., Yoon, H., Yoo, J.-Y., Lee, K.-S., & Kim, J. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212596 · Cited by 12

Brain PET motion correction using 3D face-shape model: the first clinical study

Iwao, Y., Akamatsu, G., Tashima, H., Takahashi, M., & Yamaya, T. (2022) · Annals of Nuclear Medicine · doi:10.1007/s12149-022-01774-0 · Cited by 12

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer disease: Phase 3 study

Sabri, O., Sabbagh, M. N., Seibyl, J. P., Barthel, H., Akatsu, H., Ouchi, Y., 仙田, 宏., Murayama, S., Ishii, K., Takao, M., et al. (2015) · IUScholarWorks (Indiana University) · Cited by 5

O1‐04‐01: Multicentre phase 3 trial on florbetaben for beta‐amyloid brain PET in Alzheimer's disease

Sabbagh, M. N., Seibyl, J. P., Akatsu, H., Ouchi, Y., Beach, T. G., Charny, A., Barthel, H., 仙田, 宏., Muryama, S., Ishii, K., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.220 · Cited by 6

Florbetaben to Trace Amyloid-β in the Alzheimer Brain by Means of PET

Barthel, H., & Sabri, O. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-0068 · Cited by 54

Beta-amyloid imaging with florbetaben

Sabri, O., Seibyl, J. P., Rowe, C. C., & Barthel, H. (2015) · Clinical and Translational Imaging · doi:10.1007/s40336-015-0102-6 · Cited by 177

O4‐07‐02: Efficacy and safety of florbetaben for beta‐amyloid brain positron emission tomography in Alzheimer's disease: Results from a global phase IIb trial

Osama, S., Gertz, H., Ischihara, K., Tateno, A., Drzezga, A. E., Grimmer, T., Senda, M., Yamamoto, Y., Hiemeyer, F. J., McKieth, I., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.2013 · Cited by 1